Nanoemulsions : The rising star of antiviral therapeutics and nanodelivery system-current status and prospects
© 2021 Elsevier Ltd. All rights reserved..
Nanoemulsions (NEs) of essential oil (EO) have significant potential to target microorganisms, especially viruses. They act as a vehicle for delivering antiviral drugs and vaccines. Narrowing of drug discovery pipeline and the emergence of new viral diseases, especially, coronavirus disease, have created a niche to use NEs for augmenting currently available therapeutic options. Published literature demonstrated that EOs have an inherent broad spectrum of activity across bacterial, fungal, and viral pathogens. The emulsification process significantly improved the efficacy of the active ingredients in the EOs. This article highlights the research findings and patent developments in the last 2 years especially, in EO antiviral activity, antiviral drug delivery, vaccine delivery, viral resistance development, and repurposing EO compounds against SARS-CoV-2.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
---|---|
Enthalten in: |
Current opinion in colloid & interface science - 54(2021) vom: 30. Aug., Seite 101458 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Franklyne, Jonathan Sampath [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiviral activity |
---|
Anmerkungen: |
Date Revised 21.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.cocis.2021.101458 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM323703747 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM323703747 | ||
003 | DE-627 | ||
005 | 20231225184741.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cocis.2021.101458 |2 doi | |
028 | 5 | 2 | |a pubmed24n1078.xml |
035 | |a (DE-627)NLM323703747 | ||
035 | |a (NLM)33814954 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Franklyne, Jonathan Sampath |e verfasserin |4 aut | |
245 | 1 | 0 | |a Nanoemulsions |b The rising star of antiviral therapeutics and nanodelivery system-current status and prospects |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 21.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2021 Elsevier Ltd. All rights reserved. | ||
520 | |a Nanoemulsions (NEs) of essential oil (EO) have significant potential to target microorganisms, especially viruses. They act as a vehicle for delivering antiviral drugs and vaccines. Narrowing of drug discovery pipeline and the emergence of new viral diseases, especially, coronavirus disease, have created a niche to use NEs for augmenting currently available therapeutic options. Published literature demonstrated that EOs have an inherent broad spectrum of activity across bacterial, fungal, and viral pathogens. The emulsification process significantly improved the efficacy of the active ingredients in the EOs. This article highlights the research findings and patent developments in the last 2 years especially, in EO antiviral activity, antiviral drug delivery, vaccine delivery, viral resistance development, and repurposing EO compounds against SARS-CoV-2 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Antiviral activity | |
650 | 4 | |a Drug repurposing | |
650 | 4 | |a Drug resistance | |
650 | 4 | |a Drug-delivery | |
650 | 4 | |a Microemulsion | |
650 | 4 | |a Nanoemulsion | |
650 | 4 | |a Vaccine delivery | |
700 | 1 | |a Gopinath, Ponnusamy Manogaran |e verfasserin |4 aut | |
700 | 1 | |a Mukherjee, Amitava |e verfasserin |4 aut | |
700 | 1 | |a Chandrasekaran, Natarajan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in colloid & interface science |d 1998 |g 54(2021) vom: 30. Aug., Seite 101458 |w (DE-627)NLM095552898 |x 1359-0294 |7 nnns |
773 | 1 | 8 | |g volume:54 |g year:2021 |g day:30 |g month:08 |g pages:101458 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cocis.2021.101458 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 54 |j 2021 |b 30 |c 08 |h 101458 |